Announcement of company leases and acquire
the right-of-use assets from related party
Date of events
2022/08/10
To which item it meets
paragraph 20
Statement
1.Name and nature of the underlying asset (e.g., land located at Sublot XX,
Lot XX, North District, Taichung City):
11F, No. 181, Sec. 3, Min Chuan East Road, Taipei
2.Date of occurrence of the event:2022/08/10
3.Transaction unit amount (e.g.XX square meters, equivalent to XX ping),
unit price, and total transaction price:
Lease area: 58ping
Unit price: NTD1,552(without tax)
Monthly rent: NTD90,000(without tax)
Right-of-use assets: NTD3,194,000
4.Trading counterparty and its relationship with the Company (if the trading
counterparty is a natural person and furthermore is not a related party of
the Company, the name of the trading counterparty is not required to be
disclosed):
Counterparties:Yung Shin Pharm. Ind. Co., Ltd.
Relationship with the Company: subsidiary
5.Where the trading counterparty is a related party, announcement shall also
be made of the reason for choosing the related party as trading counterparty
and the identity of the previous owner, its relationship with the Company
and the trading counterparty, and the previous date and monetary amount of
transfer:
Reason for choosing the related party as trading counterparty:
Overall operation consideration, for own business used.
The identity of the previous owner, its relationship with the Company
and the trading counterparty, and the previous date and monetary amount
of transfer:N/A
6.Where an owner of the underlying assets within the past five years has
been a related party of the Company, the announcement shall also include the
date and price of acquisition and disposal by the related party, and its
relationship with the Company at the time of the transaction:N/A
7.Projected gain (or loss) through disposal (not applicable for
acquisition of assets; those with deferral should provide a table
explaining recognition):N/A
8.Terms of delivery or payment (including payment period and
monetary amount), restrictive covenants in the contract,
and other important terms and conditions:
(1)Lease term:2022/09/01-2025/08/31
(2)Term of payment:NTD90,000(without tax)
(3)Other important terms and conditions:None
9.The manner of deciding on this transaction (such as invitation to tender,
price comparison, or price negotiation), the reference basis for the
decision on price, and the decision-making unit:
The manner of deciding on this transaction and the reference basis for the
decision on price: refer to the surrounding rental market.
The decision-making unit:Board of Directors
10.Name of the professional appraisal firm or company and
its appraisal price:N/A
11.Name of the professional appraiser:N/A
12.Practice certificate number of the professional appraiser:N/A
13.The appraisal report has a limited price, specific price,
or special price:N/A
14.An appraisal report has not yet been obtained:N/A
15.Reason for an appraisal report not being obtained:N/A
16.Reason for any significant discrepancy with the appraisal reports
and opinion of the CPA:N/A
17.Name of the CPA firm:N/A
18.Name of the CPA:N/A
19.Practice certificate number of the CPA:N/A
20.Broker and broker's fee:N/A
21.Concrete purpose or use of the acquisition or disposal:for office use
22.Any dissenting opinions of directors to the present transaction:None
23.Whether the counterparty of the current transaction is a
related party:Yes
24.Date of the board of directors resolution:2022/08/10
25.Date of ratification by supervisors or approval by
the audit committee:2022/08/08
26.The transaction is to acquire a real property or right-of-use
asset from a related party:Yes
27.The price assessed in accordance with the Article 16 of the
Regulations Governing the Acquisition and Disposal of Assets
by Public Companies:N/A
28.Where the above assessed price is lower than the transaction price,
the price assessed in accordance with the Article 17 of the same
regulations:N/A
29.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
YungShin Global Holding Corporation published this content on 10 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 August 2022 09:46:01 UTC.
YungShin Global Holding Corp is a Taiwan-based company mainly engaged in the manufacture and sale of human pharmaceutical medicine and animal medicine. The Company mainly invests in the manufacturing and trading of various medicines, animal medicines, Chinese medicines, health foods, chemicals, cosmetics, soaps, medicated soaps, various detergents, spices, feeds, diagnostic equipment and reagents. The Company also invests in the sales of pharmaceuticals, pharmaceutical raw materials and health food raw materials, as well as the production and sales of chemical drugs and feed additives and other animal products. The main products are antibiotic injection items, various aqueous solutions for medicine and oral tablets of antibiotics, veterinary drug products, medicated feed additives and non-medicated feed additives and others.